Want to see HK:2627 full AI Analyst Report?
2627 Stock Chart & Stats
HK$43.58
--
Market closed
HK$43.58
--
Day’s Range― - ―
52-Week RangeHK$28.88 - HK$73.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)183.66K
Market Cap
HK$11.54B
Enterprise ValueHK$9.93B
Total Cash (Recent Filing)HK$108.36M
Total Debt (Recent Filing)HK$931.93M
Price to Earnings (P/E)―
Beta1.32
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding296,361,850
10 Day Avg. Volume177,740
30 Day Avg. Volume183,655
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)83.89
Price to Sales (P/S)47.37
P/FCF Ratio-30.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong 2024 Revenue Rebound And Gross Margin RecoveryA large revenue rebound coupled with a dramatic gross margin swing indicates the business achieved meaningful pricing, mix or cost improvements. These changes improve the path to durable operating leverage and reduce the scale of revenue needed to reach sustainable profitability over the next several quarters.
Positive Equity Buffer On The Balance SheetMaintaining positive equity gives the company a capital cushion that reduces immediate insolvency risk and supports continued operations or negotiations with creditors. This structural buffer preserves strategic optionality for refinancing, partnerships, or asset-backed funding over 2–6 months.
Operating In Specialty & Generic PharmaceuticalsParticipation in the specialty & generic drugs sector offers durable demand drivers and product differentiation opportunities. Regulatory and manufacturing barriers in this industry can create sustainable competitive advantages for proven products, supporting longer-term revenue visibility and strategic partnerships.
Bears Say
Persistent Unprofitable Operations And Material Cash BurnOngoing operating losses and structural cash burn impair the company’s ability to self-fund growth or R&D. Without sustained margin expansion, the firm will remain dependent on external financing, increasing dilution risk and reducing strategic flexibility over the coming months.
Very Weak Cash Generation And Negative Free Cash FlowLarge negative operating and free cash flows indicate operations are not generating internal funding for capex or commercialization. This structural cash shortfall forces ongoing reliance on debt or equity raises, constraining long-term reinvestment and raising execution risk.
Elevated Leverage And Rising Debt LoadA very high debt-to-equity ratio and a sharp rise in debt reduce financial flexibility and elevate interest and covenant risk. With continued losses, leverage amplifies downside, limits strategic options, and increases the probability of distress or restrictive financing terms over the medium term.
Ab&B Bio-Tech CO., LTD. JS Class H News
2627 FAQ
What was Ab&B Bio-Tech CO., LTD. JS Class H’s price range in the past 12 months?
Ab&B Bio-Tech CO., LTD. JS Class H lowest stock price was HK$28.88 and its highest was HK$73.00 in the past 12 months.
What is Ab&B Bio-Tech CO., LTD. JS Class H’s market cap?
Ab&B Bio-Tech CO., LTD. JS Class H’s market cap is HK$11.54B.
When is Ab&B Bio-Tech CO., LTD. JS Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ab&B Bio-Tech CO., LTD. JS Class H’s earnings last quarter?
Currently, no data Available
Is Ab&B Bio-Tech CO., LTD. JS Class H overvalued?
According to Wall Street analysts Ab&B Bio-Tech CO., LTD. JS Class H’s price is currently Overvalued.
Does Ab&B Bio-Tech CO., LTD. JS Class H pay dividends?
Ab&B Bio-Tech CO., LTD. JS Class H does not currently pay dividends.
What is Ab&B Bio-Tech CO., LTD. JS Class H’s EPS estimate?
Ab&B Bio-Tech CO., LTD. JS Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ab&B Bio-Tech CO., LTD. JS Class H have?
Ab&B Bio-Tech CO., LTD. JS Class H has 296,361,850 shares outstanding.
What happened to Ab&B Bio-Tech CO., LTD. JS Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ab&B Bio-Tech CO., LTD. JS Class H?
Currently, no hedge funds are holding shares in HK:2627
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ab&B Bio-Tech CO., LTD. JS Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
Ab&B Bio-Tech CO., LTD. JS Class H
Ab&B Bio-Tech Co., Ltd. engages in the research, development, manufacturing and commercialization of innovative and traditional vaccines. Its products include quadrivalent subunit influenza and lyophilized human rabies vaccines. The company was founded by You Cai An on October 28, 2015 and is headquartered in Taizhou, China.
Technical Analysis
Hua Medicine
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
CanSino Biologics, Inc. Class H
―